Another study by Spano et al. showed that MSCs expressing TRAIL effectively targeted and killed pancreatic cancer cells in vitro and in vivo, highlighting the potential of pro-apoptotic gene-engineered MSCs in cancer therapy [49]. This evidence concerns the gene TNFSF10 and familial pancreatic carcinoma.